Source comparison
Melanotan-2 Research Review: Dosing and Outcome Comparison
Photoprotection (Levine et al., 1998) 0.025 mg/kg SC 3×/week × 4 weeks Minimal erythema dose (MED) increase 2–3× MED increase; 5–6 Pantone units darker Nausea (60–70%), flushing (40%), spontaneous erections (males, 30%) Effective photoprotection in Type I/II s
This comparison does not assign a generated winner or score.
- Photoprotection (Levine et al., 1998)
- 0.025 mg/kg SC 3×/week × 4 weeks
- Minimal erythema dose (MED) increase
- 2–3× MED increase; 5–6 Pantone units darker
- Nausea (60–70%), flushing (40%), spontaneous erections (males, 30%)
- Effective photoprotection in Type I/II skin; nausea limits adherence
- Obesity/Appetite (Greenway et al., 2009)
- 0.025 mg/kg SC daily × 14 days
- Ad libitum caloric intake reduction
- 15–22% intake reduction; 1.8 kg weight loss vs 0.3 kg placebo
- Nausea (50%), decreased libido (reported but not quantified)
- Significant appetite suppression; short trial duration limits long-term inference
- Erectile Dysfunction (Wessells et al., 2000)
- 0.0125–0.025 mg/kg SC 2–8 hrs pre-activity
- Erectile function score improvement
- 80% successful intercourse vs 20% placebo
- Nausea (50–60%), facial flushing (50%), yawning (30%)
- Clear efficacy in psychogenic ED; tolerability concerns for routine use
- Pigmentation Maintenance (Dorr et al., 2000)
- 1.0 mg SC every 72–96 hrs post-loading
- Sustained pigmentation without UV
- Stable pigmentation maintained; 4–8 week fade post-cessation
- Minimal after loading phase; occasional nausea (<10%)
- Intermittent dosing sustains effect; aligns with receptor kinetics